Trial Profile

Safety and Efficacy of a Therapy With Cladribine Following a Treatment With Anti CD20 Compounds in Relapsing Multiple Sclerosis Patients: a Pilot Study

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 06 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cladribine (Primary) ; Ocrelizumab; Rituximab
Indications Multiple sclerosis
Focus Therapeutic Use

Most Recent Events

22 Mar 2022 Status changed from recruiting to active, no longer recruiting.
12 Jan 2021 Planned End Date changed from 31 Oct 2023 to 31 Oct 2022.
12 Jan 2021 Planned primary completion date changed from 31 Oct 2023 to 31 Oct 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com